drugset

drugset / Trial / NCT02538458

Efficacy and Safety of 3% Hypertonic Saline Inhalation (24h vs 72h) to Treat Acute Bronchiolitis in Hospitalized Infants

NCT02538458 ↗

Phase 4 Completed 120 enrolled University Hospital, Grenoble AGIR à Dom · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Efficacy/Safety of 3% hypertonic saline inhalation (24H vs 72H) to treat acute bronchiolitis in infants.

Timeline

Start: 2014-11
Primary completion: 2016-03
Completion: 2016-03

Publications

Beal G, Barbier C, Thoret S, Rubio A, Bonnet M, Mazet R, Ego A, Pin I. Nebulized hypertonic saline 3% for 1 versus 3 days in hospitalized bronchiolitis: a blinded non-inferiority randomized controlled trial. BMC Pediatr. 2019 Nov 8;19(1):417. doi: 10.1186/s12887-019-1804-0.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Hypertonic saline	Unknown	3 %	Inhaled

Indications